Tenofovir does well in chronic hepatitis B treatment comparison

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.593, 2009-01, pp. : 9-9

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

By Dakin Helen Bentley Anthony Dusheiko Geoff

Value in Health, Vol. 13, Iss. 8, 2010-12 ,pp. : 922-933

Blackwell Publishing

Access to resources Recommend Favorite

Tenofovir Disoproxil Fumarate: In Chronic Hepatitis B

By Perry Caroline M. Simpson Dene

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2245-2256

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Tenofovir Disoproxil Fumarate for the Treatment of Chronic Hepatitis B from a Canadian Public Payer Perspective

By Dakin Helen Sherman Morris

PharmacoEconomics, Vol. 29, Iss. 12, 2011-12 ,pp. : 1075-1091

Adis International

Access to resources Recommend Favorite

Treatment of Chronic Hepatitis B

Current Pharmaceutical Design, Vol. 8, Iss. 11, 2002-05 ,pp. : 953-958

Bentham Science Publishers

Access to resources Recommend Favorite

First-line tenofovir best for chronic hepatitis B in Canada

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 643, 2011-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite